Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07116876 · ClinicalTrials.gov registry record · NA

Matrion Decellularized Placental Membrane Versus Conventional Wound Management in Subjects With Diabetic Foot Ulcers

A NA study of Diabetic Foot Ulcer (DFU) and Lower Extremity, sponsored by LifeNet Health.

Recruiting
Registry status
NA
Development phase
120
Enrollment target
18
Study locations

NCT07116876: Recruiting NA study of Diabetic Foot Ulcer (DFU) and Lower Extremity, sponsored by LifeNet Health.

NCT07116876 is a NA study of Diabetic Foot Ulcer (DFU) and Lower Extremity that is actively recruiting participants, run by LifeNet Health. The registered enrollment target is 120 participants, below the 509-participant average among 13 other Diabetic Foot Ulcer (DFU) trials with a reported enrollment target (76% lower). The trial reports 18 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07116876, a NA study of Diabetic Foot Ulcer (DFU) and Lower Extremity, is actively recruiting participants, sponsored by LifeNet Health.

RECRUITING
Registry status
NA
Development phase
120 participants
Enrollment target
18
Study locations

Study Summary

This study will evaluate Matrion™ (LifeNet Health, Inc., Virginia Beach, VA), a placental membrane product, as a treatment for diabetic foot ulcers compared to conventional wound care. Matrion is derived from donated human birth tissue and includes both the amniotic and chorionic layers, along with the trophoblast layer. It is minimally processed using a proprietary decellularization method and terminally sterilized to ensure the membrane is acellular and sterile, making it suitable for surgical applications.

Primary Outcome

Proportion of diabetic foot ulcers that have achieved complete wound closure

Interventions

  • OTHER Graft Application
  • OTHER Wound Dressing Material

Study Locations (18)

California

  • Bay Area Foot Care - Castro Valley
  • Limb Preservaion Platform, Inc. - Fresno
  • Center for Clinical Research, Inc - San Francisco
  • Bay Area Foot Care - San Francisco
  • ILD Research Center - Vista

Florida

  • Humanity Clinical Research, Corp - Aventura
  • South Florida Podiatry - Deerfield Beach
  • Dinamo Research & Diagnostic Center, LLC - Hialeah
  • Doctors Research Network, Inc. - Miami

Texas

  • Olympus Clinical Research - Katy
  • Element Research Group - San Antonio
  • Olympus-Alcanza - Sugar Land

Illinois

  • Independent Clinical Research - Decatur
  • Independent Clinical Research, LLC - Springfield

North Carolina

  • US Foot and Ankle Specialists - Raleigh
  • Foot and Ankle Institute of the Carolinas - Rocky Mount

Arizona

  • Compass Medical Research Center - Tucson

Virginia

  • Foot and Ankle Specialists of the Mid-Atlantic - Salem

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2025-06-26
Est. Completion 2026-06
Phase NA
LifeNet Health

8 total trials

What NCT07116876 shows while recruiting

NCT07116876 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 509-participant average among 13 other Diabetic Foot Ulcer (DFU) trials with a reported enrollment target (76% lower).

The record links to 2 conditions, with Diabetic Foot Ulcer (DFU) appearing as the primary indexed condition, and to 2 interventions - of which Graft Application is the first listed.

NCT07116876 lists 18 locations in 7 states (California, Florida, Texas).

Frequently Asked Questions

What is clinical trial NCT07116876 about?

NCT07116876 is a clinical study titled "Matrion Decellularized Placental Membrane Versus Conventional Wound Management in Subjects With Diabetic Foot Ulcers". This study will evaluate Matrion™ (LifeNet Health, Inc., Virginia Beach, VA), a placental membrane product, as a treatment for diabetic foot ulcers compared to conventional wound care. Matrion is derived from donated human birth tissue and includes both the amniotic and chorionic layers, along with ...

What is the current status of trial NCT07116876?

This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2025-06-26. Estimated completion is 2026-06.

What conditions does trial NCT07116876 study?

This clinical trial studies the following conditions: Diabetic Foot Ulcer (DFU), Lower Extremity.

What interventions are being tested in trial NCT07116876?

The interventions under investigation include: Graft Application (OTHER), Wound Dressing Material (OTHER).

Who is sponsoring clinical trial NCT07116876?

This trial is sponsored by LifeNet Health, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07116876 being conducted?

This trial has 18 study locations across Arizona, California, Florida, Illinois, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetic Foot Ulcer (DFU)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07116876's enrollment target sits among peer trials

120 11th of 13 higher than 3 of 13 other Diabetic Foot Ulcer (DFU) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetic Foot Ulcer (DFU) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07116876, the US trial registry maintained by the National Library of Medicine. NCT07116876 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.